Back to results
US 11,701,409 B2Granted
Dosing and use of long-acting CLR/ramp agonists
AssigneeAdepthera LLC
InventorSheau Yu Teddy Hsu
Life of this patent
Estimating the term…
Abstract
Long-acting agonistic analogs for CLR/RAMP receptors are provided that have an extended half-live in vivo. The agonists are delivered to an individual at a dose sufficient to reduce hypertension and ischemic injury, and to reduce cardiotoxicity associated with chemotherapeutic agents.
Claims8
A method for reducing cardiotoxicity, the method comprising:
- administering a long-acting CLR/RAMP receptor agonist peptide selected from the group consisting of SEQ ID NO:4;
- SEQ ID NO:5;
- SEQ ID NO:6;
- SEQ ID NO:7;
- SEQ ID NO:8;
- SEQ ID NO:9;
- SEQ ID NO:10;
- SEQ ID NO:11;
- SEQ ID NO:12;
- SEQ ID NO:13;
- SEQ ID NO:14;
- SEQ ID NO:15;
- SEQ ID NO:16;
- SEQ ID NO:17;
- SEQ ID NO:18;
- SEQ ID NO:19;
- SEQ ID NO:20;
- SEQ ID NO:21;
- SEQ ID NO:22;
- SEQ ID NO:23;
- SEQ ID NO:25;
- SEQ ID NO:26;
- SEQ ID NO:28;
- SEQ ID NO:31;
- SEQ ID NO:32;
- SEQ ID NO:34, to a subject in need thereof at a dose of at least about 0.5 g/kg weight for a period of time sufficient to reduce cardiotoxicity.
23 more elements
A method for reducing cardiotoxicity, the method comprising:
- administering subcutaneously a long-acting CLR/RAMP receptor agonist consisting of the amino acid sequence set forth in SEQ ID NO:18 to a subject in need thereof at a dose of at least about 0.5 g/kg weight for a period of time sufficient to reduce cardiotoxicity.
Dependencies are inferred from the claim text.